Advances in Topical Management of Adolescent Facial and Truncal Acne: A Phase 3 Pooled Analysis of Safety and Efficacy of Trifarotene 0.005% Cream.

Abstract

PURPOSE:

Acne vulgaris is very common among adolescents and young adults. It is important for clinicians who provide care to these patients to have a plan of action for assessing and managing acne in daily practice.

METHODS:

Post-hoc analysis of two large-scale phase 3 pivotal trials of trifarotene 0.005% cream, focusing on efficacy, safety, and tolerability in the subgroup of subjects aged 12 to 17, inclusive.

RESULTS:

Trifarotene was effective and well tolerated on both the face and trunk in patients ages 12-17 with moderate acne. There was a low and acceptable rate of adverse events and tolerability was favorable.

CONCLUSIONS:

Trifarotene monotherapy was associated with good clinical efficacy, safety, and tolerability. Once-daily application offers convenience for patients, and the low concentration of trifarotene makes it well-suited to use on large skin areas such as the trunk. J Drugs Dermatol. 2022;21(6):582-586. doi:10.36849/JDD.6778.

• Authors: Lawrence Eichenfield, Pearl Kwong, Stephanie Lee, Daniel Krowchuk, Krysten Arekapudi, Adelaide Hebert
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 21 Issue 6 Pg. 582-586 (Jun 01 2022) ISSN: 1545-9616 [Print] United States
• PMID: 35674762 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Retinoids
• trifarotene

Topics

• Acne Vulgaris (drug therapy)
• Adolescent
• Child
• Clinical Trials, Phase III as Topic
• Humans
• Retinoids (administration & dosage, adverse effects)
• Skin Cream (administration & dosage, adverse effects)
• Treatment Outcome